Technical Analysis for ZGNX - Zogenix, Inc.

Grade Last Price % Change Price Change
grade D 43.49 1.26% 0.54
ZGNX closed up 1.26 percent on Tuesday, October 22, 2019, on 37 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Up
See historical ZGNX trend table...

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
50 DMA Resistance Bearish 1.26%
MACD Bullish Centerline Cross Bullish 1.26%
Overbought Stochastic Strength 1.26%
Fell Below 200 DMA Bearish 2.11%
Fell Below 50 DMA Bearish 2.11%
Stochastic Sell Signal Bearish 2.11%
Expansion Pivot Sell Setup Bearish Swing Setup 2.11%
Upper Bollinger Band Walk Strength 2.11%
Weak + Overbought Other 2.11%

Older signals for ZGNX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. Its commercial product includes Sumavel DosePro (sumatriptan injection), a delivery system that offers needle-free subcutaneous administration of sumatriptan for the acute treatment of migraine and cluster headache. The company's lead product candidate, Zohydro, a single-entity extended-release hydrocodone, which has completed Phase III clinical trials for the treatment of moderate to severe chronic pain requiring around-the-clock opioid therapy. It is also developing Relday, an injectable formulation of risperidone, which is in a Phase I clinical trial to treat the symptoms of schizophrenia and bipolar disorder in adults and teenagers with 13 years of age and older. Zogenix, Inc. markets and sells its Sumavel DosePro to wholesale pharmaceutical distributors and retail pharmacies in the United States. It has a licensing and distribution agreement with Desitin Arzneimittel GmbH to develop and commercialize DosePro in the European Union, Norway, Switzerland, and Turkey. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was founded in 2006 and is headquartered in San Diego, California.
Chemistry Pharmaceutical Pain Schizophrenia Central Nervous System Disorders Morphinans Neurochemistry Cell Signaling European Union Migraine Ketones Treatment Of Central Nervous System Disorders Treatment Of Migraine Hydrocodone Severe Chronic Pain Bipolar Disorder Indoles Retail Pharmacies Triptans
Is ZGNX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 56.5
52 Week Low 33.43
Average Volume 464,337
200-Day Moving Average 44.4537
50-Day Moving Average 43.393
20-Day Moving Average 41.366
10-Day Moving Average 42.2
Average True Range 1.388
ADX 23.58
+DI 25.0989
-DI 14.4792
Chandelier Exit (Long, 3 ATRs ) 40.726
Chandelier Exit (Short, 3 ATRs ) 42.6182
Upper Bollinger Band 44.2871
Lower Bollinger Band 38.4449
Percent B (%b) 0.86
BandWidth 14.123193
MACD Line 0.1445
MACD Signal Line -0.339
MACD Histogram 0.4835
Fundamentals Value
Market Cap 1.08 Billion
Num Shares 24.8 Million
EPS -3.42
Price-to-Earnings (P/E) Ratio -12.72
Price-to-Sales 35.07
Price-to-Book 12.08
PEG Ratio -0.43
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 45.05
Resistance 3 (R3) 45.04 44.51 44.79
Resistance 2 (R2) 44.51 44.11 44.52 44.70
Resistance 1 (R1) 44.00 43.87 44.26 44.01 44.62
Pivot Point 43.47 43.47 43.60 43.48 43.47
Support 1 (S1) 42.96 43.07 43.22 42.97 42.36
Support 2 (S2) 42.43 42.83 42.44 42.28
Support 3 (S3) 41.92 42.43 42.19
Support 4 (S4) 41.93